Clinical-stage pre-IPO biotech company is leveraging translational science to extend the healthy lives of beloved companions; this offering is limited to accredited investors. BOSTON , Sept. 19, 2024 /PRNewswire/ -- CureLab Veterinary Inc.
, a pioneer in developing innovative veterinary therapeutics to combat cancer and inflammatory diseases in pets, has initiated a Regulation D fundraising offering . The offering is being conducted pursuant to Rule 506(c) of Regulation D promulgated under the Securities Act of 1933, as amended. The company is seeking to raise up to $15,000,000 and the offering is now open only to accredited investors .
Proceeds from the offering will be used to obtain conditional market authorization from the USDA for the company's flagship product, ElenaVet TM , establish a USDA-certified DNA/RNA manufacturing facility, and achieve profitability — which is projected within four years. Addressing the growing need for pet cancer treatments The veterinary cancer market is experiencing significant growth, with the global market for cat and dog cancer therapeutics projected to see double-digit growth for years to come. The increasing prevalence of cancer in pets, coupled with the growing trend of pet humanization, highlights the urgent need for effective and accessible treatment options.
CureLab Veterinary is committed to addressing this unmet need and improving the lives of pets and their families. Innovative science, compassionate care "At CureLab Veterinary.